{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:07:24Z","timestamp":1788570444774,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40256-024-00693-x","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:32:06Z","timestamp":1732163526000},"page":"169-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost Effectiveness of Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5174-4788","authenticated-orcid":false,"given":"Luxzup","family":"Wattanasukchai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunlaphat","family":"Bubphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-2167","authenticated-orcid":false,"given":"Montarat","family":"Thavorncharoensap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-3954","authenticated-orcid":false,"given":"Sitaporn","family":"Youngkong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-9823","authenticated-orcid":false,"given":"Usa","family":"Chaikledkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-386X","authenticated-orcid":false,"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"693_CR1","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1161\/CIR.0000000000000568","volume":"137","author":"LY Chen","year":"2018","unstructured":"Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137:e623\u201344. https:\/\/doi.org\/10.1161\/CIR.0000000000000568.","journal-title":"Circulation"},{"key":"693_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"6","key":"693_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/ehjqcco\/qcaa061","volume":"7","author":"H Dai","year":"2021","unstructured":"Dai H, Zhang Q, Much AA, Maor E, Segev A, Beinart R, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990\u20132017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574\u201382. https:\/\/doi.org\/10.1093\/ehjqcco\/qcaa061.","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"693_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16:217\u201321. https:\/\/doi.org\/10.1177\/1747493019897870.","journal-title":"Int J Stroke"},{"key":"693_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century. Circ Res. 2020;127:4\u201320. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316340.","journal-title":"Circ Res"},{"key":"693_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/jamacardio.2018.1176","volume":"3","author":"AS Go","year":"2018","unstructured":"Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation. JAMA Cardiol. 2018;3:601. https:\/\/doi.org\/10.1001\/jamacardio.2018.1176.","journal-title":"JAMA Cardiol."},{"key":"693_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIR.0000000000001193","volume":"2024","author":"JA Joglar","year":"2023","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;2024:149. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","journal-title":"Circulation"},{"key":"693_CR8","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140:e125\u201351. https:\/\/doi.org\/10.1161\/CIR.0000000000000665.","journal-title":"Circulation"},{"issue":"5","key":"693_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/europace\/eux373","volume":"20","author":"G-A Dan","year":"2018","unstructured":"Dan G-A, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5):731\u2013732an. https:\/\/doi.org\/10.1093\/europace\/eux373.","journal-title":"Europace"},{"key":"693_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1074248416651722","volume":"22","author":"JW Waks","year":"2017","unstructured":"Waks JW, Zimetbaum P. Antiarrhythmic drug therapy for rhythm control in atrial fibrillation. J Cardiovasc Pharmacol Ther. 2017;22:3\u201319. https:\/\/doi.org\/10.1177\/1074248416651722.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"693_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2019.10929","volume":"322","author":"GA Upadhyay","year":"2019","unstructured":"Upadhyay GA, Alenghat FJ. Catheter ablation for atrial fibrillation in 2019. JAMA. 2019;322:686. https:\/\/doi.org\/10.1001\/jama.2019.10929.","journal-title":"JAMA"},{"key":"693_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12916-022-02385-2","volume":"20","author":"E Charitakis","year":"2022","unstructured":"Charitakis E, Metelli S, Karlsson LO, Antoniadis AP, Rizas KD, Liuba I, et al. Comparing efficacy and safety in catheter ablation strategies for atrial fibrillation: a network meta-analysis. BMC Med. 2022;20:193. https:\/\/doi.org\/10.1186\/s12916-022-02385-2.","journal-title":"BMC Med"},{"issue":"34","key":"693_CR13","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta12340","volume":"12","author":"M Rodgers","year":"2008","unstructured":"Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess. 2008;12(34):iii\u2013iv. https:\/\/doi.org\/10.3310\/hta12340. (xi\u2013xiii, 1\u2013198).","journal-title":"Health Technol Assess"},{"key":"693_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40273-013-0028-7","volume":"31","author":"B Br\u00fcggenj\u00fcrgen","year":"2013","unstructured":"Br\u00fcggenj\u00fcrgen B, Kohler S, Ezzat N, Reinhold T, Willich SN. Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation. Pharmacoeconomics. 2013;31:195\u2013213. https:\/\/doi.org\/10.1007\/s40273-013-0028-7.","journal-title":"Pharmacoeconomics"},{"key":"693_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1471-2261-13-78","volume":"13","author":"M Neyt","year":"2013","unstructured":"Neyt M, Van Brabandt H, Devos C. The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations. BMC Cardiovasc Disord. 2013;13:78. https:\/\/doi.org\/10.1186\/1471-2261-13-78.","journal-title":"BMC Cardiovasc Disord"},{"key":"693_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"693_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","volume":"16","author":"CC Adarkwah","year":"2016","unstructured":"Adarkwah CC, van Gils PF, Hiligsmann M, Evers SMAA. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16:513\u201323. https:\/\/doi.org\/10.1586\/14737167.2015.1103185.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"693_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12913-022-07595-1","volume":"22","author":"BS Bagepally","year":"2022","unstructured":"Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, Attia J, Thakkinstian A. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022;22(1):202. https:\/\/doi.org\/10.1186\/s12913-022-07595-1.","journal-title":"BMC Health Serv Res"},{"key":"693_CR19","unstructured":"IMF. Consumer Price Index (CPI). IMF DATA. 2023."},{"key":"693_CR20","unstructured":"IMF. Implied PPP conversion rate. World Econ Outlook. 2023."},{"key":"693_CR21","unstructured":"World Bank. World bank country and lending groups. World Dev Indic database. 2023."},{"key":"693_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10198-021-01275-3","volume":"22","author":"K Chaiyakittisopon","year":"2021","unstructured":"Chaiyakittisopon K, Pattanaprateep O, Ruenroengbun N, Sapankaew T, Ingsathit A, Mckay GJ, et al. Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations. Eur J Heal Econ. 2021;22:571\u201384. https:\/\/doi.org\/10.1007\/s10198-021-01275-3.","journal-title":"Eur J Heal Econ."},{"issue":"4","key":"693_CR23","doi-asserted-by":"publisher","first-page":"ofz117","DOI":"10.1093\/ofid\/ofz117","volume":"6","author":"S Haider","year":"2019","unstructured":"Haider S, Chaikledkaew U, Thavorncharoensap M, Youngkong S, Islam MA, Thakkinstian A. Systematic review and meta-analysis of cost-effectiveness of rotavirus vaccine in low-income and lower-middle-income countries. Open Forum Infect Dis. 2019;6(4):ofz117. https:\/\/doi.org\/10.1093\/ofid\/ofz117.","journal-title":"Open Forum Infect Dis"},{"key":"693_CR24","unstructured":"Deeks JJ, Higgins JP, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins J, Thomas J, Chandler J, et al. (editors). Cochrane handbook for systematic reviews of interventions version 65 (updated August 2024). Cochrane; 2024. www.training.cochrane.org\/handbook."},{"key":"693_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-14-139","volume":"14","author":"C Crespo","year":"2014","unstructured":"Crespo C, Monleon A, D\u00edaz W, R\u00edos M. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC Med Res Methodol. 2014;14:139. https:\/\/doi.org\/10.1186\/1471-2288-14-139.","journal-title":"BMC Med Res Methodol"},{"key":"693_CR26","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. (editors). Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane; 2023. www.training.cochrane.org\/handbook."},{"key":"693_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97\u2013111. https:\/\/doi.org\/10.1002\/jrsm.12.","journal-title":"Res Synth Methods."},{"key":"693_CR28","volume-title":"Stata statistical software: release 18","author":"StataCorp","year":"2023","unstructured":"StataCorp. Stata statistical software: release 18. College Station: StataCorp LLC; 2023."},{"key":"693_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3111\/13696998.2014.911185","volume":"17","author":"LH Anderson","year":"2014","unstructured":"Anderson LH, Black EJ, Civello KC, Martinson MS, Kress DC. Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation. J Med Econ. 2014;17:481\u201391. https:\/\/doi.org\/10.3111\/13696998.2014.911185.","journal-title":"J Med Econ"},{"issue":"4","key":"693_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cjca.2023.11.019","volume":"40","author":"JG Andrade","year":"2024","unstructured":"Andrade JG, Moss JWE, Kuniss M, Sadri H, Wazni DO, Sale A, et al. The cost-effectiveness of first-line cryoablation versus first-line antiarrhythmic drugs in Canadian patients with paroxysmal atrial fibrillation. Can J Cardiol. 2024;40(4):576\u201384. https:\/\/doi.org\/10.1016\/j.cjca.2023.11.019.","journal-title":"Can J Cardiol"},{"key":"693_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/europace\/euu188","volume":"17","author":"M Aronsson","year":"2015","unstructured":"Aronsson M, Walfridsson H, Janzon M, Walfridsson U, Nielsen JC, Hansen PS, et al. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace. 2015;17:48\u201355. https:\/\/doi.org\/10.1093\/europace\/euu188.","journal-title":"Europace"},{"key":"693_CR32","doi-asserted-by":"publisher","first-page":"E011237","DOI":"10.1161\/CIRCEP.122.011237","volume":"16","author":"AE Berman","year":"2023","unstructured":"Berman AE, Kabiri M, Wei T, Galvain T, Sha Q, Kuck K-H. Economic and health value of delaying atrial fibrillation progression using radiofrequency catheter ablation. Circ Arrhythmia Electrophysiol. 2023;16:E011237. https:\/\/doi.org\/10.1161\/CIRCEP.122.011237.","journal-title":"Circ Arrhythmia Electrophysiol."},{"key":"693_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/26280","volume":"2013","author":"G Blackhouse","year":"2013","unstructured":"Blackhouse G, Assasi N, Xie F, Gaebel K, Campbell K, Healey JS, et al. Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation. Int J Vasc Med. 2013;2013:1\u201311. https:\/\/doi.org\/10.1155\/2013\/26280.","journal-title":"Int J Vasc Med."},{"key":"693_CR34","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/j.jacc.2006.01.070","volume":"47","author":"PS Chan","year":"2006","unstructured":"Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2006;47:2513\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2006.01.070.","journal-title":"J Am Coll Cardiol"},{"key":"693_CR35","doi-asserted-by":"publisher","first-page":"E007094","DOI":"10.1161\/CIRCOUTCOMES.120.007094","volume":"13","author":"DS Chew","year":"2020","unstructured":"Chew DS, Loring Z, Anand J, Fudim M, Lowenstern A, Rymer JA, et al. Economic evaluation of catheter ablation of atrial fibrillation in patients with heart failure with reduced ejection fraction. Circ Cardiovasc Qual Outcomes. 2020;13:E007094. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.120.007094.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"693_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCULATIONAHA.122.058575","volume":"146","author":"DS Chew","year":"2022","unstructured":"Chew DS, Li Y, Cowper PA, Anstrom KJ, Piccini JP, Poole JE, et al. Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation: The CABANA randomized clinical trial. Circulation. 2022;146:535\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.058575.","journal-title":"Circulation"},{"key":"693_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40256-019-00349-1","volume":"19","author":"X Du","year":"2019","unstructured":"Du X, He X, Jia Y, Wu J, Long D, Yu R, et al. A long-term cost-effectiveness analysis comparing radiofrequency catheter ablation with antiarrhythmic drugs in treatment of Chinese patients with atrial fibrillation. Am J Cardiovasc Drugs. 2019;19:569\u201377. https:\/\/doi.org\/10.1007\/s40256-019-00349-1.","journal-title":"Am J Cardiovasc Drugs"},{"key":"693_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4022\/jafib.195","volume":"1","author":"N Eckard","year":"2009","unstructured":"Eckard N, Davidson T, Walfridsson H, Levin L-A. Cost-effectiveness of catheter ablation treatment for patients with symptomatic atrial fibrillation. J Atr Fibrillation. 2009;1:461\u201370. https:\/\/doi.org\/10.4022\/jafib.195.","journal-title":"J Atr Fibrillation."},{"key":"693_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031033","volume":"9","author":"L Gao","year":"2019","unstructured":"Gao L, Moodie M. Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure. BMJ Open. 2019;9: e031033. https:\/\/doi.org\/10.1136\/bmjopen-2019-031033.","journal-title":"BMJ Open"},{"key":"693_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.gaceta.2009.08.004","volume":"24","author":"MJL Gude","year":"2010","unstructured":"Gude MJL, Bezos DR, Barrios JMR. Cost-utility analysis of concomitant atrial fibrillation management in Spain. Gac Sanit. 2010;24:59\u201365. https:\/\/doi.org\/10.1016\/j.gaceta.2009.08.004.","journal-title":"Gac Sanit"},{"key":"693_CR41","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jval.2021.10.014","volume":"25","author":"M Hu","year":"2022","unstructured":"Hu M, Han Y, Zhao W, Chen W. Long-term cost-effectiveness comparison of catheter ablation and antiarrhythmic drugs in atrial fibrillation treatment using discrete event simulation. Value Health. 2022;25:975\u201383. https:\/\/doi.org\/10.1016\/j.jval.2021.10.014.","journal-title":"Value Health."},{"key":"693_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36469\/9837","volume":"3","author":"Y Khaykin","year":"2016","unstructured":"Khaykin Y, Mallow PJ, Rizzo JA, Verma A, Chun L, Olesovsky S, et al. Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy for the treatment of atrial fibrillation: a Canadian perspective. J Heal Econ Outcomes Res. 2016;3:1\u201312. https:\/\/doi.org\/10.36469\/9837.","journal-title":"J Heal Econ Outcomes Res."},{"key":"693_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcvm.2023.1062578","volume":"10","author":"W Kim","year":"2023","unstructured":"Kim W, Kim M, Kim YT, Park W, Kim J, Kim C, et al. Cost-effectiveness of rhythm control strategy: ablation versus antiarrhythmic drugs for treating atrial fibrillation in Korea based on real-world data. Front Cardiovasc Med. 2023;10:1\u20139. https:\/\/doi.org\/10.3389\/fcvm.2023.1062578.","journal-title":"Front Cardiovasc Med."},{"key":"693_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019599","author":"D Lau","year":"2021","unstructured":"Lau D, Sandhu RK, Andrade JG, Ezekowitz J, So H, Klarenbach S. Cost-utility of catheter ablation for atrial fibrillation in patients with heart failure: an economic evaluation. J Am Heart Assoc. 2021. https:\/\/doi.org\/10.1161\/JAHA.120.019599.","journal-title":"J Am Heart Assoc"},{"key":"693_CR45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jce.15317","volume":"33","author":"LWM Leung","year":"2022","unstructured":"Leung LWM, Imhoff RJ, Marshall HJ, Frame D, Mallow PJ, Goldstein L, et al. Cost-effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom. J Cardiovasc Electrophysiol. 2022;33:164\u201375. https:\/\/doi.org\/10.1111\/jce.15317.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"693_CR46","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/hrt.2008.147165","volume":"95","author":"C McKenna","year":"2008","unstructured":"McKenna C, Palmer S, Rodgers M, Chambers D, Hawkins N, Golder S, et al. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. Heart. 2008;95:542\u20139. https:\/\/doi.org\/10.1136\/hrt.2008.147165.","journal-title":"Heart"},{"issue":"3","key":"693_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s41669-023-00471-6","volume":"8","author":"JWE Moss","year":"2024","unstructured":"Moss JWE, Todd D, Grodzicki L, Palazzolo B, Mattock R, Mealing S, et al. An economic evaluation of a streamlined day-case atrial fibrillation ablation protocol and conventional cryoballoon ablation versus antiarrhythmic drugs in a UK paroxysmal atrial fibrillation population. PharmacoEcon Open. 2024;8(3):417\u201329. https:\/\/doi.org\/10.1007\/s41669-023-00471-6.","journal-title":"PharmacoEcon Open."},{"issue":"3","key":"693_CR48","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.hroo.2022.09.011","volume":"O2","author":"J Osorio","year":"2022","unstructured":"Osorio J, Mansour M, Melby D, Imhoff RJ, Hunter TD, Maccioni S, et al. Economic evaluation of contact force catheter ablation for persistent atrial fibrillation in the United States. Heart Rhythm. 2022;O2(3):647\u201355. https:\/\/doi.org\/10.1016\/j.hroo.2022.09.011.","journal-title":"Heart Rhythm"},{"key":"693_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad122.688\/7177176","volume":"11","author":"J Paisey","year":"2024","unstructured":"Paisey J, Moss J, Andrade J, Kuniss M, Wazni O, Chierchia GB, et al. Economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from an English National Health Service perspective. Open Heart. 2024;11: e002423. https:\/\/doi.org\/10.1093\/europace\/euad122.688\/7177176.","journal-title":"Open Heart."},{"key":"693_CR50","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/europace\/eut380","volume":"16","author":"MR Reynolds","year":"2014","unstructured":"Reynolds MR, Lamotte M, Todd D, Khaykin Y, Eggington S, Tsintzos S, et al. Cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. Europace. 2014;16:652\u20139. https:\/\/doi.org\/10.1093\/europace\/eut380.","journal-title":"Europace"},{"key":"693_CR51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/CIRCEP.108.837294","volume":"2","author":"MR Reynolds","year":"2009","unstructured":"Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythmia Electrophysiol. 2009;2:362\u20139. https:\/\/doi.org\/10.1161\/CIRCEP.108.837294.","journal-title":"Circ Arrhythmia Electrophysiol."},{"key":"693_CR52","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jval.2023.08.008","volume":"26","author":"M Serra-Burriel","year":"2023","unstructured":"Serra-Burriel M, Aebersold H, Foster-Witassek F, Coslovsky M, Rodondi N, Blum MR, et al. Real-world cost-effectiveness of pulmonary vein isolation for atrial fibrillation: a target trial approach. Value Health. 2023;26:1721\u20139. https:\/\/doi.org\/10.1016\/j.jval.2023.08.008.","journal-title":"Value Health."},{"key":"693_CR53","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.hroo.2023.07.007","volume":"4","author":"O Wazni","year":"2023","unstructured":"Wazni O, Moss J, Kuniss M, Andrade J, Chierchia GB, Mealing S, et al. An economic evaluation of first-line cryoballoon ablation vs antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a U.S. Medicare perspective. Hear Rhythm O2. 2023;4:528\u201337. https:\/\/doi.org\/10.1016\/j.hroo.2023.07.007.","journal-title":"Hear Rhythm O2"},{"issue":"1","key":"693_CR54","volume":"2","author":"N Assasi","year":"2012","unstructured":"Assasi N, Blackhouse G, Xie F, Gaebel K, Robertson D, Hopkins R, et al. ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses. CADTH Technol Overv. 2012;2(1): e2101.","journal-title":"CADTH Technol Overv."},{"key":"693_CR55","unstructured":"Ollendorf DA, Silverstein MD, Bobo T, Steven D. Pearson. Rhythm control and stroke prevention strategies for patients with atrial fibrillation [Internet]. Massachusetts; 2010. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/Atrial-Fibrillation-Final-09-24-10.pdf. Accessed 1 Apr 2024."},{"key":"693_CR56","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","volume":"25","author":"J Kazibwe","year":"2022","unstructured":"Kazibwe J, Gheorghe A, Wilson D, Ruiz F, Chalkidou K, Chi YL. The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review. Value Health. 2022;25:385\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.08.014.","journal-title":"Value Health."},{"issue":"4","key":"693_CR57","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/00019053-200018040-00002","volume":"18","author":"MP Teng","year":"2000","unstructured":"Teng MP, Catherwood E, Melby DP. Cost effectiveness of therapies for atrial fibrillation. Pharmacoeconomics. 2000;18(4):317\u201333. https:\/\/doi.org\/10.2165\/00019053-200018040-00002.","journal-title":"Pharmacoeconomics"},{"key":"693_CR58","volume-title":"China guidelines for pharmacoeconomic evaluations","year":"2020","unstructured":"Liu GG, Hu S, Wu J, Wu J, Dong Z, Li H, editors. China guidelines for pharmacoeconomic evaluations. 2020th ed. Beijing: Chinese Pharmaceutical Association. ISPOR; 2020.","edition":"2020"},{"key":"693_CR59","unstructured":"World Bank. The World Bank In China [Internet]. Where we Work. 2023 [cited 24 May 2024]. Available from: https:\/\/www.worldbank.org\/en\/country\/china\/overview."},{"issue":"12","key":"693_CR60","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s40273-020-00954-y","volume":"38","author":"J Ochalek","year":"2020","unstructured":"Ochalek J, Wang H, Gu Y, Lomas J, Cutler H, Jin C. Informing a cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach. Pharmacoeconomics. 2020;38(12):1319\u201331. https:\/\/doi.org\/10.1007\/s40273-020-00954-y.","journal-title":"Pharmacoeconomics"},{"key":"693_CR61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10198-021-01384-z","volume":"23","author":"D Cai","year":"2022","unstructured":"Cai D, Shi S, Jiang S, Si L, Wu J, Jiang Y. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Heal Econ. 2022;23:607\u201315. https:\/\/doi.org\/10.1007\/s10198-021-01384-z.","journal-title":"Eur J Heal Econ."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00693-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00693-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00693-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:28:19Z","timestamp":1739172499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00693-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00693-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"13 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Luxzup Wattanasukchai, Tunlaphat Bubphan, Montarat Thavorncharoensap, Sitaporn Youngkong, Usa Chaikledkaew, and Ammarin Thakkinstian declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors conceptualized and designed the study. LW and TB extracted the data. LW analyzed and interpreted the data. All authors drafted the manuscript and provided critical feedback. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"The Center for Ethics in Human Research, Khon Kaen University has confirmed that no ethical approval is required for this systematic review.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}